Trial Profile
A Retrospective Cohort Study Assessing the HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2018
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Pharmacodynamics; Therapeutic Use
- 05 Apr 2018 New trial record
- 01 Apr 2018 Results published in the Anticancer Research Journal.